background
bronchoalveolar
lavag
bal
util
diagnos
lung
infiltr
immunocompromis
heterogen
data
report
diagnost
yield
rang
therefor
select
criteria
bal
maxim
yield
minim
complic
unclear
object
studi
determin
diagnost
yield
complic
rate
bal
immunocompromis
patient
present
lung
infiltr
identifi
factor
impact
outcom
exploratori
aim
includ
character
pathogen
rate
treatment
modif
mortal
method
retrospect
studi
januari
decemb
patient
mechan
ventil
exclud
posit
diagnost
yield
defin
confirm
microbiolog
cytolog
diagnosi
result
total
patient
recruit
male
mean
age
year
diagnost
yield
complic
rate
complic
hypoxemia
endobronchi
bleed
selllimit
treatment
modif
base
bal
result
infecti
aetiolog
identifi
hiv
infect
ci
p
sever
neutropenia
ci
p
associ
posit
yield
leukemia
ci
p
associ
lower
yield
factor
impact
complic
rate
overal
mortal
hematolog
malign
conclus
bal
retain
util
diagnosi
immunocompromis
patient
lung
infiltr
howev
patient
hematolog
malign
high
mortal
altern
sampl
consid
poor
result
bal
trial
registr
clinicaltrialsgov
identifi
regist
june
lung
infiltr
caus
signific
morbid
mortal
immunocompromis
patient
howev
heterogen
group
variou
aetiolog
underli
immunosuppress
infecti
diseas
societi
america
guidelin
includ
definit
highli
immunocompromis
patient
follow
group
combin
immunodefici
disord
chemotherapi
cancer
month
postsolid
organ
transplant
human
immunodefici
viru
hiv
infect
tlymphocyt
count
cell
mm
daili
corticosteroid
treatment
dose
mg
prednison
equival
day
use
biolog
immun
modul
tumor
necrosi
factoralpha
blocker
rituximab
moreov
clinic
practic
patient
hematolog
malign
neutropenia
steroidspar
immunosuppress
also
consid
immunocompromis
despit
heterogen
underli
etiolog
major
patient
lung
infiltr
present
similar
manner
cough
fever
dyspnea
empir
treatment
without
risk
includ
advers
drug
reaction
inadequaci
therapi
develop
antimicrobi
resist
therefor
obtain
confirm
diagnosi
essenti
sinc
therapeut
paradigm
vari
wide
depend
caus
lung
infiltr
addit
earli
diagnosi
associ
improv
surviv
data
report
confirm
diagnosi
within
day
lower
mortal
compar
later
diagnosi
vs
p
flexibl
bronchoscopi
commonli
use
investig
lung
infiltr
facilit
collect
microbiolog
cytolog
sampl
via
bronchoalveolar
lavag
bal
perform
ambulatori
set
complic
procedur
includ
hypoxemia
myocardi
ischemia
data
diagnost
yield
bal
immunocompromis
patient
present
lung
infiltr
rang
complic
rate
rang
tabl
mark
heterogen
data
inclus
criteria
studi
design
make
challeng
draw
definit
conclus
patient
like
benefit
bal
prognosi
variou
group
categor
accord
underli
caus
immunosuppress
addit
limit
data
countri
tuberculosi
endem
primari
object
studi
determin
diagnost
yield
bal
immunocompromis
patient
present
lung
infiltr
patient
alreadi
progress
respiratori
failur
requir
mechan
ventil
mortal
rate
nearli
need
consid
separ
popul
beyond
scope
studi
addit
aim
determin
incid
complic
bal
identifi
factor
associ
either
higher
diagnost
yield
lower
complic
rate
exploratori
aim
includ
character
commonli
isol
pathogen
rate
postprocedur
treatment
modif
indic
clinic
util
well
postprocedur
mortal
postprocedur
treatment
modif
reflect
true
valu
procedur
sinc
microbiolog
find
may
nonpathogen
commens
result
may
amend
clinic
intervent
identif
data
optim
patient
select
allow
endoscopist
counsel
patient
recommend
altern
diagnost
modal
low
likelihood
success
diagnosi
high
risk
complic
retrospect
crosssect
studi
evalu
immunocompromis
patient
radiograph
evid
neutropenia
sever
categor
base
absolut
neutrophil
count
mild
per
microlit
moder
per
microlit
sever
per
microlit
exclus
criteria
compris
bal
perform
icu
set
mechan
ventil
patient
due
differ
procedur
bronchoscop
intub
via
endotrach
tube
prognosi
also
differ
poor
patient
progress
respiratori
failur
patient
underw
transbronchi
lung
biopsi
form
bronchoscop
sampl
also
exclud
avoid
introduct
confound
factor
data
extract
bronchoscopi
databas
prospect
collect
via
endoscopist
report
bronchoscopi
detail
perform
hospit
endoscopi
centr
ensur
integr
complet
data
collect
studi
period
data
render
nonidentifi
remov
patient
name
identif
card
number
date
procedur
chest
comput
tomographi
ct
scan
interpret
radiologist
consult
pulmonologist
predomin
abnorm
character
accord
follow
categori
consolid
ground
glass
opac
treeinbud
appear
reticular
infiltr
nodular
infiltr
cavit
institut
review
board
approv
obtain
singhealth
centralis
institut
review
board
refer
number
clinicaltrialsgov
identifi
waiver
consent
provid
singhealth
centralis
institut
review
board
bronchoscopi
perform
use
olympu
olympu
tokyo
japan
bronchoscop
outer
diamet
mm
mm
work
channel
procedur
perform
moder
sedat
use
combin
fentanyl
midazolam
bal
obtain
bronchopulmonari
segment
correspond
ct
scan
find
focal
infiltr
right
middl
lobe
lingular
prefer
case
diffus
infiltr
bal
sampl
sent
standard
investig
consist
cytolog
microbiolog
analysi
microscopi
bacteria
perform
gram
stain
acid
fast
bacilli
ziehlneelsen
stain
pneumocysti
jirovecii
gomori
methenamin
silver
follow
bacteri
fungal
mycobacteri
cultur
polymeras
chain
reaction
test
perform
mycobacterium
tuberculosi
tbprotec
respiratori
virus
influenza
parainfluenza
respiratori
syncyti
viru
coronaviru
adenoviru
rhinoviru
metapneumoviru
cytomegaloviru
detect
bal
fluid
antigen
assay
cellbas
viru
isol
consid
pathogen
presenc
either
intracellular
inclus
bodi
cytolog
concomit
posit
serum
antigenemia
galactomannan
antigen
perform
via
enzymelink
immunosorb
assay
primari
outcom
diagnost
yield
defin
number
bal
posit
diagnost
studi
divid
total
number
patient
posit
studi
defin
either
confirm
diagnosi
cytolog
microbiolog
postbal
treatment
modif
consid
posit
treatment
document
initi
escal
discontinu
respons
diagnost
bal
find
treatment
chang
keep
bal
find
patient
followedup
minimum
month
subgroup
analysi
perform
accord
underli
caus
immunosuppress
patient
classifi
group
hiv
posit
patient
ongo
hematolog
malign
other
hiv
neg
nonhematolog
malign
complic
consid
associ
bronchoscopi
occur
periprocedur
within
h
patient
underw
procedur
complic
rate
calcul
number
procedur
complic
divid
total
number
procedur
perform
complic
classifi
six
categori
use
common
terminolog
criteria
advers
event
ctcae
definitionssever
pneumothorax
airway
bleed
hypoxia
hypotens
requir
escal
level
care
statist
analys
perform
use
statist
softwar
spss
ibm
corp
releas
ibm
spss
statist
window
version
armonk
ny
ibm
corp
find
consid
statist
signific
analys
pvalu
continu
variabl
summar
use
mean
standard
deviat
sd
median
interquartil
rang
iqr
categor
variabl
summar
use
frequenc
fisher
exact
test
student
test
mannwhitney
u
test
appropri
use
compar
categor
continu
variabl
respect
secondari
outcom
analyz
use
logist
regress
factor
unadjust
odd
ratio
univari
logist
regress
satisfi
criteria
pvalu
includ
multivari
logist
regress
analysi
determin
adjust
odd
ratio
factor
significantli
associ
diagnost
yield
complic
rate
flexibl
bronchoscopi
bal
perform
immunocompromis
patient
januari
decemb
one
hundr
fiftytwo
patent
male
mean
age
year
fiftynin
patient
fever
common
present
symptom
follow
cough
dyspnea
median
durat
symptom
day
iqr
patient
receiv
empir
antibiot
prior
bronchoscopi
median
durat
day
iqr
ct
chest
scan
obtain
patient
consolid
common
find
follow
ground
glass
opac
ct
scan
perform
median
day
iqr
prior
bal
procedur
patient
characterist
present
tabl
median
durat
bronchoscopi
min
iqr
follow
sedat
use
median
midazolam
mg
iqr
fentanyl
microgram
iqr
median
volum
bal
fluid
instil
ml
iqr
instil
volum
retriev
case
overal
diagnost
yield
studi
postprocedur
treatment
modif
base
bal
result
major
posit
bal
yield
infecti
agent
case
pneumocysti
jirovecii
mycobacteria
tuberculosi
rhinoviru
cytomegaloviru
found
case
inclus
bodi
identifi
cytolog
tabl
show
bal
microbiolog
result
galactomannan
test
also
posit
case
antigen
index
consid
posit
noninfecti
caus
pulmonari
infiltr
found
case
base
cytolog
clinicalradiolog
present
eosinophil
pneumonia
squamou
cell
carcinoma
lung
adenocarcinoma
druginduc
pneumon
differ
characterist
patient
posit
neg
bal
outlin
tabl
multivari
logist
regress
analysi
factor
significantli
associ
higher
diagnost
yield
includ
hiv
infect
overal
complic
rate
studi
attribut
selflimit
hypoxemia
requir
supplement
oxygen
therapi
temporarili
ctcae
remain
two
case
endobronchi
bleed
requir
endoscop
intervent
ctcae
patient
thrombocytopen
platelet
count
per
microlit
per
microlit
patient
requir
intub
escal
care
postprocedur
mortal
respect
patient
suffer
complic
significantli
higher
median
charlson
comorbid
index
median
iqr
compar
suffer
complic
median
iqr
p
univari
logist
regress
analysi
complic
rate
found
dyspnea
diseas
present
significantli
associ
increas
complic
unadjust
ci
p
multivari
logist
regress
analysi
found
factor
significantli
associ
complic
rate
see
supplementari
materi
appendix
nonhiv
hematolog
malign
patient
diagnost
yield
case
impact
patient
manag
treatment
modif
isol
pathogen
includ
case
parainfluenza
viru
pseudomona
aeruginosa
rhinoviru
respiratori
syncyti
viru
mycobacterium
tuberculosi
klebsiella
speci
coronaviru
complic
rate
postprocedur
mortal
respect
mortal
rate
significantli
higher
nonhiv
hematolog
malign
patient
hiv
nonhiv
nonhematolog
malign
group
nonhiv
nonhematolog
malign
patient
diagnost
yield
result
modif
therapi
pathogen
includ
case
mycobacterium
tuberculosi
human
coronaviru
aspergillu
speci
pneumocysti
jirovecii
rhinoviru
case
pseudomona
aeruginosa
complic
rate
postprocedur
mortal
respect
test
proport
indic
mortal
rate
significantli
differ
least
one
categori
hiv
patient
nonhiv
hematolog
malign
patient
nonhiv
nonhematolog
malign
patient
compar
other
p
diagnost
yield
bal
immunocompromis
patient
present
lung
infiltr
ambulatori
set
major
case
posit
bal
find
impact
clinic
manag
infecti
etiolog
account
posit
diagnos
reinforc
current
clinic
practic
earli
use
empir
antibiot
addit
studi
found
impact
prior
antimicrobi
therapi
durat
antibiot
diagnost
yield
mismatch
posit
yield
postbal
result
treatment
modif
may
attribut
fact
pathogen
detect
respiratori
virus
therapeut
option
limit
addit
none
isol
cytomegaloviru
inclus
bodi
detect
correspond
cytolog
rais
doubt
pathogen
natur
cytomegaloviru
isol
case
bal
cytomegaloviru
isol
find
includ
antigenemia
label
posit
diagnost
yield
case
pneumocysti
jirovecii
case
tuberculosi
case
aspergillosi
case
pseudomona
infect
addit
bal
galactomannan
posit
also
show
differ
diagnost
yield
differ
group
base
caus
underli
immunosuppress
hiv
patient
highest
diagnost
yield
major
posit
pneumocysti
jirovecii
result
identifi
group
also
meant
postbal
treatment
modif
lowest
group
pneumocysti
pneumonia
often
clinic
diagnosi
appropri
empir
treatment
alreadi
commenc
also
trend
toward
increas
risk
post
procedur
hypoxia
hiv
patient
endoscopist
note
respect
ensur
appropri
postprocedur
monitor
previou
data
hiv
patient
show
diagnost
yield
mix
group
hiv
patient
show
yield
contrast
diagnost
yield
lower
patient
hematolog
malign
especi
leukaemia
possibl
explan
noninfect
aetiolog
alveolar
haemorrhag
may
preval
group
bal
procur
cytolog
histolog
specimen
analysi
condit
drug
induc
pneumon
may
pathognomon
find
may
difficult
establish
confirm
caus
diagnosi
exclus
therefor
altern
sampl
includ
lung
biopsi
consid
earli
patient
hematolog
malign
nonhiv
nonhematolog
malign
patient
diagnost
yield
hiv
patient
hematolog
malign
group
pertin
find
group
commonli
identifi
pathogen
mycobacteria
tuberculosi
may
reflect
endem
natur
tuberculosi
popul
singapor
well
natur
immunosuppress
find
corrobor
presenc
radiolog
evid
cavit
patient
trend
toward
increas
diagnost
yield
cavit
inde
present
complic
rate
signific
entir
selflimit
trend
toward
higher
rate
patient
higher
comorbid
burden
hypox
present
comorbid
like
impact
effect
moder
sedat
cardiorespiratori
system
hypoxemia
may
exacerb
introduct
salin
lavag
degre
decruit
bronchoscop
suction
studi
also
confirm
earlier
data
prognosi
immunocompromis
patient
pulmonari
infiltr
guard
vari
underli
caus
immunosuppress
allcaus
mortal
rang
hiv
patient
respect
hematolog
malign
prior
data
show
mortal
haematolog
patient
neutropen
patient
mix
aetiolog
studi
mortal
nonhematolog
malign
hematolog
malign
reflect
sever
ill
immunocompromis
patient
pulmonari
infiltr
serv
impetu
continu
improv
bronchoscop
sampl
laboratori
test
symptom
radiolog
find
besid
trend
presenc
cavit
also
impact
diagnost
yield
studi
therefor
identifi
patient
unlik
get
bronchoscop
diagnosi
basi
clinic
present
may
challeng
delay
diagnosi
due
neg
bal
result
may
also
risk
clinic
deterior
limit
studi
includ
retrospect
design
howev
fact
data
extract
prospect
bronchoscopi
databas
directli
popul
endoscopist
report
ensur
complet
data
addit
procedur
detail
collect
standard
format
sampl
size
may
also
lack
statist
power
detect
factor
associ
complic
low
complic
rate
final
data
limit
singl
institut
studi
howev
meant
bal
sampl
microscop
test
perform
standard
manner
flexibl
bronchoscopi
bal
retain
role
manag
immunocompromis
patient
present
lung
infiltr
especi
establish
confirm
microbiolog
diagnosi
diagnosi
possibl
complic
larg
selflimit
howev
diagnost
yield
vari
underli
caus
immunosuppress
altern
sampl
consid
earli
patient
hematolog
malign
poor
result
bal
group
haematolog
malign
high
mortal
delay
diagnosi
risk
clinic
deterior
tuberculosi
appear
import
pathogen
endem
region
especi
nonhiv
nonhematolog
malign
group
aspergillu
commonli
identifi
pathogen
via
cultur
galactomannan
assay
virus
account
posit
diagnosi
find
often
lead
limit
modif
clinic
manag
data
show
util
limit
bal
approach
immunocompromis
patient
present
lung
infiltr
data
serv
foundat
newer
therapeut
strategi
transbronchi
cryobiopsi
evalu
